Elanco Animal Health Inc
NYSE:ELAN
Elanco Animal Health Inc
Elanco Animal Health Inc. emerged from the hallowed halls of Eli Lilly and Company, officially standing on its own in 2018, and immediately carving out its identity as a key player in animal health. The company, headquartered in Greenfield, Indiana, prides itself on working at the intersection of science and animal well-being, bringing innovative solutions to the market. Elanco's operations revolve around two primary business segments: Companion Animal and Farm Animal. In the Companion Animal segment, the focus is squarely on developing products that improve the health and extend the lives of pets, from flea and tick treatments to vaccines that safeguard them against disease. This segment taps into the growing humanization of pets, leveraging the emotional bond between owners and animals to drive demand for premium pet healthcare products.
On the other hand, Elanco's Farm Animal segment is deeply woven into the fabric of the agricultural ecosystem, serving the needs of livestock operations around the globe. This division offers a suite of products that enhance the health and productivity of cattle, swine, poultry, and aqua species, addressing concerns from disease prevention to growth efficiency. By providing antibiotics, vaccines, and other nutritional health additives, Elanco helps farmers meet the world's growing demand for protein while complying with the ever-stringent regulations on animal product safety and efficacy. The company's diversified portfolio and its global reach allow it to monetize the vast and varied animal health landscape effectively, positioning itself as a stalwart in the sector dedicated not just to animal care but to elevating the industry standards through innovation and responsible growth.
Elanco Animal Health Inc. emerged from the hallowed halls of Eli Lilly and Company, officially standing on its own in 2018, and immediately carving out its identity as a key player in animal health. The company, headquartered in Greenfield, Indiana, prides itself on working at the intersection of science and animal well-being, bringing innovative solutions to the market. Elanco's operations revolve around two primary business segments: Companion Animal and Farm Animal. In the Companion Animal segment, the focus is squarely on developing products that improve the health and extend the lives of pets, from flea and tick treatments to vaccines that safeguard them against disease. This segment taps into the growing humanization of pets, leveraging the emotional bond between owners and animals to drive demand for premium pet healthcare products.
On the other hand, Elanco's Farm Animal segment is deeply woven into the fabric of the agricultural ecosystem, serving the needs of livestock operations around the globe. This division offers a suite of products that enhance the health and productivity of cattle, swine, poultry, and aqua species, addressing concerns from disease prevention to growth efficiency. By providing antibiotics, vaccines, and other nutritional health additives, Elanco helps farmers meet the world's growing demand for protein while complying with the ever-stringent regulations on animal product safety and efficacy. The company's diversified portfolio and its global reach allow it to monetize the vast and varied animal health landscape effectively, positioning itself as a stalwart in the sector dedicated not just to animal care but to elevating the industry standards through innovation and responsible growth.
Revenue Beat: Elanco delivered Q4 revenue growth of 12% and 9% organic constant currency, outperforming the high end of guidance.
Strong Innovation: 2025 innovation revenue reached $892 million, exceeding expectations; 2026 innovation guidance raised to $1.15 billion.
Share Gains: Elanco gained U.S. pet health share in every major category and rapidly expanded Zenrelia's international market share.
Margins & Cash: Adjusted gross margin improved 30 bps to 51.2% in Q4, and net leverage ratio declined to 3.6x, ahead of schedule.
2026 Guidance: 2026 organic constant currency revenue growth expected at 4-6%, adjusted EBITDA at $955-985 million (up 8%), and adjusted EPS of $1 to $1.06 (up 10%).
Product Portfolio: Credelio Quattro and Zenrelia continued to drive strong sales and portfolio benefits; Befrena launch planned for Q2 2026.
Productivity & Cost: Elanco Ascend productivity program is on track, targeting $25 million in 2026 savings.
Strategic M&A: Announced acquisition of a Dutch-based cattle health innovator (AHV) to enhance dairy portfolio.
